ArticleFrontiers in pharmacology2026
Impact of the 2017 ACC/AHA hypertension guidelines on antihypertensive prescribing in the United States: real-world evidence from a nationally representative population.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fixed-dose combinationFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension (HTN) remains a major contributor to cardiovascular morbidity and mortality in the United States (US). The 2017 ACC/AHA HTN guidelines introduced major changes to diagnostic thresholds and treatment recommendations, including earlier pharmacological initiation and greater emphasis on combination therapy. However, the long-term, population-level impact of these guidelines on antihypertensive medication utilization in the US remains uncharacterized. Methods: We conducted a pooled cross-sectional study using data from the Medical Expenditure Panel Survey (2013-2022). Adults ≥18 years with diagnosed HTN were included. Antihypertensive classes utilization was defined as any use of the medication class with ≥2 prescription refills within the same year among eligible participants. Utilization of antihypertensive classes was then pooled and examined across two periods: pre-guidelines (2013-2017) and post-guidelines (2018-2022). Survey-weighted multivariable logistic regression models were used to assess the impact of the 2017 ACC/AHA guidelines on the overall utilization of antihypertensive drug classes and within subgroups with compelling indications. Results: A total of 29,901 adults were included. Following guidelines implementation, angiotensin receptor blockers (ARBs) utilization increased from 18% to 26% (adjusted OR [aOR] = 1.35; 95% confidence interval [CI]: 1.21-1.50, p < 0.0001), and calcium channel blocker (CCB) use increased from 28% to 32% (aOR = 1.24; 95% CI: 1.13-1.36, p < 0.0001). In contrast, fixed-dose combination (FDC) utilization declined from 22% to 16% (aOR = 0.67; 95% CI: 0.59-0.75, p < 0.0001). Utilization of other antihypertensive classes did not change significantly. Conclusion: After the 2017 ACC/AHA guidelines update, antihypertensive prescribing in the US showed increased use of ARBs and CCBs. However, declining FDC use highlights a persistent gap between evidence-based guidance and real-world practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.